7th Drug Formulation, Solubility & Bioavailability -

7th Drug Formulation, Solubility & Bioavailability
March 26 - 28, 2018
Boston, MA

The Modeling and Enabled Formulation Expertise You need to Maximize Developability, Avoid Particle Formation, and Maintain Stability and Bioavailability

Agenda – 7th Drug Formulation, Solubility & Bioavailability



Advances in Drug Delivery Seminar

 Monday, March 26, 2018

8:45AM – 9:00AM

INTRODUCTION FROM SEMINAR CHAIRPERSON


Joachim Hoechel, Head, Clinical Pharmacology, BAYER

9:00AM – 9:45AM

ALTERNATIVES TO ORAL DOSING ROUTES


Meena Venugopal, Vice President, Biopharmaceutics, ALVOGEN

9:45AM – 10:30AM

PANEL: ACHIEVE BREAKTHROUGHS IN ORAL BIOLOGICS DELIVERY


Moderator:
Rakesh Dixit, Vice President, R&D, Global Head, Biologics Safety Assessment, MEDIMMUNE

10:30AM – 11:00AM

Networking Break


11:00AM – 11:45AM

ENCAPSULATION AND RELEASE OF PEPTIDES AND BIOLOGICS AT HIGHER LOADINGS THAN W/O/W EMULSIONS FOR NANOPARTICLE AND DEPOT MICROPARTICLE DELIVERY


Robert Prud’homme, Professor, Chemical and Biological Engineering, PRINCETON UNIVERSITY

11:45AM – 12:30PM

MAKE ADVANCES IN LONG-ACTING INJECTABLE DELIVERY OF PEPTIDES


Liping Zhou, Head of Formulation Development, RA PHARMACEUTICALS

12:30PM – 1:15PM

DEVELOP LONG-ACTING PARENTERAL AND DEPOT DELIVERY SYSTEMS AND MODELS TO DESIGN AND PREDICT SUCCESS IN THE CLINIC


Jaymin Shah, Research Fellow, Pharmaceutical Sciences, Parenteral Development Centre of Emphasis, PFIZER

1:15PM – 2:15PM

Luncheon


2:15PM – 3:00PM

SOLUBILITY AND FORMULATION APPROACHES FOR INJECTABLE DRUGS


Neera Jain, Senior Director, CMC, SYROS PHARMACEUTICALS

3:00PM – 3:45PM

TARGETED TISSUE DELIVERY: DREAM OF THE DECADE


Ruchi Gupta, Scientist, MEDIMMUNE

3:45PM – 4:30PM

MAINTAIN NECESSARY FLEXIBILITY IN THE CLINICAL TESTING AND PRODUCTION OF SOLID DOSAGE TABLETS


Joachim Hoechel, Head, Clinical Pharmacology, BAYER


Day 1

 Tuesday, March 27, 2018

9:00AM – 9:15AM

CHAIRPERSON’S OPENING REMARKS


Keith Horspool, Vice President, Pharmaceutics, BOEHRINGER INGELHEIM

 NEW SKILLS AND TECHNOLOGIES FOR DRUG DESIGN

9:15AM – 10:00AM

PHARMA FORMULATION ASSUMPTIONS AND THE IMPORTANCE OF PATIENT INPUT TO ENABLE FORMULATION INNOVATION


Manuel Sanchez-Felix, Senior Fellow, Formulations, NOVARTIS

10:45AM – 11:15AM

Networking Break


11:15AM – 12:00PM

LEVERAGE UNDERSTANDING OF SELF-ASSOCIATION TO ENHANCE FORMULATION PERFORMANCE


Fady Ibrahim, Principal Scientist, PFIZER

12:00PM – 12:45PM

PANEL:  PROSPECTS OF VIRTUAL OR ULTRA-RAPID DEVELOPMENT USING A PLATFORM OF IN SILICO TECHNOLOGY


Moderator:
Keith Horspool, Vice President, Pharmaceutics, BOEHRINGER INGELHEIM

Rossitza Alargova, Director, Formulations, INFINITY PHARMACEUTICALS
Eric Munson, Professor, Pharmaceutical Technology, UNIVERSITY OF KENTUCKY
Dedong Wu, Senior Scientist, ASTRAZENECA

12:45PM – 1:45PM

Luncheon


 

NEXT GENERATION MODELING

1:45PM – 2:00PM
INTRODUCTION FROM TRACK CHAIR

Manuel Sanchez-Felix, Senior Fellow, Formulations, NOVARTIS

2:00PM – 2:45PM
IDENTIFY THE CORRECT MODELS FOR SELECTING MULTIPLE FORMULATION OPTIONS

Robert Saklatvala, Director, Basic Pharmaceutical Sciences, MERCK

2:45PM – 3:30PM
IN SILICO SOLID STATE MODELING IN DRUG SUBSTANCE FORM DEVELOPMENT

Dedong Wu, Senior Scientist, ASTRAZENECA

3:30PM – 4:15PM
PREDICTIVE ANALYTICS FOR AMORPHOUS SOLID DISPERSION STABILITY

Eric Munson, Professor, Pharmaceutical Technology, UNIVERSITY OF KENTUCKY

REFINING FORMULATION STRATEGY

2:00PM – 2:45PM
GET LONG-TERM STABILITY ANSWERS IN THE SHORTEST TIME POSSIBLE

Fenghe Qiu, Senior Research Fellow, BOEHRINGER INGELHEIM

2:45PM – 3:30PM
NANOPARTICLE FORMULATIONS FOR ENHANCED BIOAVAILABILITY AND STABILITY

Robert Prud’homme, Professor, Chemical and Biological Engineering, PRINCETON UNIVERSITY

3:30PM – 4:15PM
IDENTIFY THE THRESHOLDS IN LOW-SOLUBILITY COMPOUNDS THAT MUST TRIGGER YOUR DEVELOPMENT OF ENABLED FORMULATIONS

Rossitza Alargova, Director, Formulations, INFINITY PHARMACEUTICALS

 

4:15PM – 4:45PM

Networking Break


 

4:45PM – 5:30PM
DETERMINE IF FOOD EFFECTS CAN BE MEANINGFULLY PREDICTED

Andy Zhu, Head, Preclinical Oncology Modeling and Simulations, TAKEDA

5:30PM – 6:15PM
EMPIRICALLY EXPLORE THE LIMITATIONS OF PREDICTIVE TOOLS

Emilija Fredro-Kumbaradzi, Manager, Biowaivers and Biocorrelations, APOTEX

4:45PM – 5:30PM
DETERMINE COMPOUND SUITABILITY FOR NANOPARTICLE FORMULATIONS

Ghazal Hariri, Senior Scientist, Global R&D, PFIZER

5:30PM – 6:15PM
ADAPT TO FORMULATION CHANGES WHEN APPROACHING FIRST-IN-HUMAN STUDIES

James Huckle, Scientist, Basic Pharmaceutics, Oral Delivery Product and Process Development, AMGEN

 


Day 2

 Wednesday, March 28, 2018

8:00AM – 9:00AM

Continental Breakfast


9:00AM – 9:15AM

CHAIRPERSON’S RECAP OF DAY ONE


Keith Horspool, Vice President, Pharmaceutics, BOEHRINGER INGELHEIM

 MANAGING COMMON FORMULATION SETBACKS

9:15AM – 10:00AM

SHORTEN THE BRIDGE FROM PRECLINICAL TO CLINICAL DATA GATHERING


Joachim Hoechel, Head, Clinical Pharmacology, BAYER

10:00AM – 10:45AM

OVERCOME THE HIGH FAILURE RATE OF IVIVC


Wen Lin, Senior Investigator, NOVARTIS

10:45AM – 11:15AM

Networking Break


11:15AM – 12:00PM

COMPARE ADVANTAGES AND DISADVANTAGES OF MULTIPLE OPTIONS FOR AMORPHOUS FORMULATION DEVELOPMENT


Karthik Nagapudi, Senior Scientist, GENENTECH

12:00PM – 12:45PM

ENGINEER AMORPHOUS SOLID DISPERSIONS FOR DRUG DELIVERY


Pavithra Sundararajan, Assistant Principal Scientist, Preclinical Development, MERCK

12:45PM – 1:45PM

Luncheon


1:45PM – 2:30PM

FOCUS ON THE PROCESS OF OPTIMIZATION WITHIN R&D


Gail Dempsey, EOC and Director, Manufacturing Technologies, PIEDMONT ANIMAL HEALTH


live chat software